|
Market Closed -
Nasdaq
23:00:00 26/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 148.09 USD | -0.46% |
|
+0.33% | +20.65% |
| 08-25 | Wall Street Wants Receipts |  |
| 08-25 | Lakefront Biotherapeutics, Gilead Secure Another Orphan Drug Designation for Skin Disorder Drug in US | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 184B | - | ||||
| 1,100B | |||||
| 658B | - | - | - | ||
| 470B | |||||
| 372B | |||||
| 304B |
- Stock Market
- Stocks
- GILD Stock
- Charts Gilead Sciences, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
